Travoprost (Travatan)

A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Also Known As:

Travatan; (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; AL-6221; AL6221; Travatan Z; AL 6221; Z, Travatan

Networked: 338 relevant articles (55 outcomes, 93 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Konstas, Anastasios G P: 10 articles (01/2015 - 03/2006)
2.	Bergamini, Michael V W: 10 articles (06/2008 - 08/2002)
3.	Stewart, William C: 8 articles (11/2010 - 03/2003)
4.	Landry, Theresa A: 7 articles (06/2008 - 07/2005)
5.	Hubatsch, Douglas A: 6 articles (01/2017 - 11/2014)
6.	Mizoue, Shiro: 6 articles (01/2017 - 01/2014)
7.	Holló, Gábor: 6 articles (09/2013 - 12/2005)
8.	Denis, Philippe: 6 articles (01/2012 - 01/2006)
9.	Voskanyan, Lilit: 5 articles (01/2020 - 08/2014)
10.	Kahook, Malik Y: 5 articles (06/2014 - 04/2008)

Related Diseases

1.	Open-Angle Glaucoma (Glaucoma, Open Angle) 10/01/2014 - "The present study demonstrated the long-term 24-hour efficacy of travoprost for the treatment of primary open-angle glaucoma." 10/01/2014 - "The aim of the study was to evaluate the long-term 24-hour intraocular pressure (IOP) efficacy of travoprost monotherapy in primary open-angle glaucoma patients. " 04/01/2009 - "This study suggests that when both drugs are dosed in the evening the TTFC provides improved intraocular pressure reduction, compared with travoprost, over the 24 h curve and for each individual time point in primary open-angle glaucoma patients." 01/01/2019 - "To study the hypotensive efficacy and safety of Travapress (0.004% travoprost) in patients with primary open-angle glaucoma (POAG). " 06/01/2023 - "Analysing the change in contrast sensitivity post-travoprost treatment in primary open-angle glaucoma patients using Spaeth Richman contrast sensitivity test."
2.	Ocular Hypertension (Glaucoma, Suspect) 02/01/2013 - "Alternate day use of travoprost 0.004% was as safe and effective as its daily use in lowering the IOP in patients with ocular hypertension." 02/01/2013 - "Fourteen patients with ocular hypertension in both eyes have been randomly assigned to receive travoprost 0.004% once a day in 1 eye and once every other day in the other eye. " 02/01/2013 - "To compare the daily versus the alternate day use of travoprost 0.004% in lowering the intraocular pressure (IOP) in patients with ocular hypertension. " 02/01/2013 - "A short-term randomized clinical trial of daily versus alternate day use of travoprost 0.004% in the treatment of ocular hypertension." 05/01/2003 - "Two prospective, controlled, multicenter, double-masked studies--one lasting 6 months (n=594) and the other, 12 months (n=787)--examined the intraocular pressure (IOP)-lowering efficacy of travoprost in 1381 black and nonblack patients with open-angle glaucoma or ocular hypertension. "
3.	Glaucoma 10/21/2010 - "The proven efficacy and safety combined with convenient once-daily dosing for travoprost increases patient compliance with treatment for glaucoma." 07/01/2019 - "This study will evaluate the efficacy of travoprost for patients with glaucoma systematically. " 07/01/2019 - "Efficacy of travoprost for the treatment of patients with glaucoma." 12/01/2022 - "According to our study, it can be suggested that travoprost spanlastic nano-vesicles ocular insert is a novel ocular delivery system for glaucoma treatment." 01/01/2020 - "This study aimed to compare QoL and correlate it with OSD in glaucoma patients receiving BAC-preserved and BAC-free travoprost. "
4.	Low Tension Glaucoma 01/01/2012 - "BAK-free travoprost monotherapy was effective in reducing intraocular pressure for at least 3 years; however, visual field performance worsened in 2.8%-13.9% of patients with normal tension glaucoma." 01/01/2014 - "This study aimed to evaluate the effect of travoprost with sofZia® preservative system for lowering the intraocular pressure (IOP) of Japanese normal tension glaucoma (NTG) patients. " 08/01/2008 - "The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial." 01/01/2014 - "The diurnal and nocturnal effects of travoprost in normal-tension glaucoma." 01/01/2014 - "Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects."
5.	Hyperemia 10/01/2017 - "The most common treatment-related adverse events for the travoprost group were ocular hyperemia and eyelash growth. " 08/01/2015 - "Hyperemia was the most frequent treatment-related adverse event with both formulations (travoprost 0.003%, 11.8%; travoprost 0.004%, 14.5%). " 01/01/2007 - "Adverse events due to hyperemia occurred in 6.4% and 9.0% of patients treated with travoprost 0.004% without BAC and travoprost 0.004% with BAC, respectively. " 01/01/2003 - "Travoprost is a safe drug, with local side effects including hyperemia, eyelash growth and iris color change. " 09/01/2008 - "Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p < 0.0001). "

Related Drugs and Biologics

1.	Timolol (Blocadren)
2.	Latanoprost (Xalatan)
3.	Bimatoprost (Lumigan)
4.	Travoprost (Travatan)
5.	Ophthalmic Solutions (Eye Drops)
6.	brinzolamide (Azopt)
7.	Synthetic Prostaglandins (Prostaglandin Analogues)
8.	Benzalkonium Compounds (Benzalkonium Chloride)
9.	tafluprost
10.	dorzolamide (Trusopt)

Related Therapies and Procedures

1.	Therapeutics
2.	Stents
3.	Phacoemulsification
4.	Slit Lamp
5.	Vitrectomy